Theratechnologies Inc. (NASDAQ:THTX) Short Interest Update

Theratechnologies Inc. (NASDAQ:THTX - Get Free Report) was the recipient of a significant drop in short interest in the month of March. As of March 15th, there was short interest totalling 41,900 shares, a drop of 13.6% from the February 28th total of 48,500 shares. Approximately 0.2% of the shares of the stock are sold short. Based on an average daily volume of 199,200 shares, the short-interest ratio is presently 0.2 days.

Wall Street Analyst Weigh In

Separately, Research Capitl raised shares of Theratechnologies to a "strong-buy" rating in a report on Friday, February 14th.

Theratechnologies Stock Up 10.1 %

Shares of THTX stock traded up $0.15 on Monday, reaching $1.63. 313,491 shares of the stock were exchanged, compared to its average volume of 297,690. The stock has a market cap of $74.90 million, a P/E ratio of -16.25 and a beta of 1.11. Theratechnologies has a 1-year low of $1.08 and a 1-year high of $2.18. The firm has a 50 day moving average of $1.61 and a two-hundred day moving average of $1.50.

Institutional Trading of Theratechnologies

Large investors have recently modified their holdings of the business. Raymond James Financial Inc. purchased a new stake in Theratechnologies during the 4th quarter worth approximately $27,000. Bank of America Corp DE raised its stake in Theratechnologies by 1,416.7% during the fourth quarter. Bank of America Corp DE now owns 16,487 shares of the company's stock valued at $30,000 after buying an additional 15,400 shares in the last quarter. JPMorgan Chase & Co. acquired a new position in Theratechnologies in the fourth quarter worth $33,000. BNP Paribas Financial Markets acquired a new stake in shares of Theratechnologies during the 4th quarter worth approximately $36,000. Finally, Virtu Financial LLC bought a new stake in Theratechnologies in the fourth quarter valued at $40,000.

Remove Ads

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.